Product Description
Mechanisms of Action: ACE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypertension
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2005-003521-13 | P3 |
Completed |
Unknown |
2008-03-20 |
|
RAVEL-1 | P3 |
Completed |
Hypertension |
2008-03-01 |
|
2006-7041-83/hah | N/A |
Not yet recruiting |
Spinal Cord Injuries |
None |